In a study evaluating the BioNTech-Pfizer COVID-19 vaccine's ability to neutralize the B.1.1.7 ("UK") viral variant, researchers found no loss of immune protection compared to that against the original Wuhan reference strain. Their analysis was based on blood samples from 40 people who had received the BioNTech-Pfizer COVID-19 vaccine during clinical trials.
The authors conclude their results show it is "unlikely that the UK variant virus will escape ... protection" as mediated by this vaccine.
In September 2020, the SARS-CoV-2 lineage B.1.1.7 was discovered in the United Kingdom. It subsequently increased in prevalence, showed enhanced transmissibility, and spread to other continents. The B.1.1.7 variant has a series of mutations in its spike (S) protein, which it uses to gain entry to host cells.
Whether a virus with the large number of mutations found in the spike protein of lineage B.1.1.7 could be neutralized by the blood sera from people who had received the BioNTech-Pfizer COVID-19 vaccine is an important question.
To investigate, the authors generated SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein. They tested these viruses with blood sera of 40 people who had received the BioNTech-Pfizer COVID-19 vaccine following the recommended regimen of two doses administered 21 days apart. The sera had slightly reduced but largely preserved neutralizing titers against the B.1.1.7 lineage pseudovirus, they found. This suggests the UK variant won't "escape" vaccine-mediated protection, as provided by this vaccine.
The authors note that the non-replicating pseudovirus system they used may be a potential limitation of the study. They also conclude: "Although sustained neutralization of the current B.1.1.7 variant is reassuring, preparation for potential COVID-19 vaccine strain change is prudent. Adaptation of the vaccine to a new virus strain would be facilitated by the flexibility of mRNA-based vaccine technology."
https://science.sciencemag.org/content/early/2021/01/28/science.abg6105
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fneutralization-of-sars&filter=22
Pfizer COVID-19 vaccine largely effective against UK variant
- 1,742 views
- Added
Edited
Latest News
Manipulating mitochondrial…
By newseditor
Posted 07 Dec
Guiding cells to natural ta…
By newseditor
Posted 07 Dec
Mechanism of nucleolar vacu…
By newseditor
Posted 06 Dec
Traumatic memories can rewi…
By newseditor
Posted 06 Dec
The tongue might also detec…
By newseditor
Posted 06 Dec
Other Top Stories
Insight into cause of Alzheimer's symptoms
Read more
New insights on how cocaine changes the brain
Read more
Nitric oxide mediates glial-induced neurodegeneration
Read more
Regulation of remyelination by endothelin receptor
Read more
Mechanism of synapse elimination in Alzheimer's disease
Read more
Protocols
Brain-wide circuit-specific…
By newseditor
Posted 05 Dec
Cheap, cost-effective, and…
By newseditor
Posted 03 Dec
Temporally multiplexed imag…
By newseditor
Posted 02 Dec
Efficient elimination of ME…
By newseditor
Posted 01 Dec
Personalized drug screening…
By newseditor
Posted 30 Nov
Publications
rRNA intermediates coordina…
By newseditor
Posted 06 Dec
Epigenomic dissection of Al…
By newseditor
Posted 06 Dec
Activity-dependent organiza…
By newseditor
Posted 06 Dec
Innate immunity: the bacter…
By newseditor
Posted 06 Dec
The proton channel OTOP1 is…
By newseditor
Posted 06 Dec
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar